All In Biotech

Drug Trial Radar · NCT04736186

Prevention and Treatment of Pyrrolitinib-associated Diarrhea

Prevention and Treatment of Pyrrolitinib-associated Diarrhea: a Prospective, Multicenter, Open-label Clinical Study

Last checked: Nov 19, 2026Latest source record: Feb 3, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 470 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

470

Planned (sponsor's estimate)

Start

May 16, 2020

Primary completion

Oct 31, 2022

Study completion Apr 30, 2023

Sponsor

Lead sponsor
Tianjin Medical University Cancer Institute and HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Feb 3, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

In this study, patients taking pyrrolitinib alone or combined with pyrrolitinib were recruited (170 cases of secondary prevention and 300 cases of non-secondary prevention). Non-secondary prevention: Explore the recovery time of oral loperamide 4mg T.I.D. for pyrrolitinib induced diarrhea of 1-2 degrees. Secondary prevention: To explore the incidence of grade 3 and above diarrhea during c1D1-C1D22 in patients with oral loperamide 4 mg, T.I.D. (D1-7) →4 mg, B.I.D. (D8-21).

Conditions

  • Breast Cancer

Interventions

  • LoperamideDrug

    Loperamide 4 mg, t.i.d.(d 1-7);4 mg, b.i.d.(d 8-21)

  • Loperamide and golden bifidDrug

    Patients with secondary prevention will be randomly assigned to B:Loperamide 4 mg, t.i.d.(d 1-7);4 mg, b.i.d.(d 8-21)+golden bifid 2 g t.i.d.

  • Loperamide and montmorillonite powderDrug

    Patients with secondary prevention will be randomly assigned to D:Loperamide 4 mg, t.i.d.(d 1-7);4 mg, b.i.d.(d 8-21)+montmorillonite powder 3 g t.i.d.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. time from the first day of treatment until diarrhea returns to level 0 or baseline during the first day of treatment to the 22nd day of treatmentTime frame: From the first day of treatment to the 22nd day of treatment(about 21 days)
  2. The proportion of 3/4 degree diarrhea in group A From the first day of treatment to the 22nd day of treatmentTime frame: From the first day of treatment to the 22nd day of treatment(about 21 days)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • TianJin Medical University Cancer Institute and Hospital

    Tianjin, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.